Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Canopy Growth CorporationNASDAQ: CGC
Capital Expenditures · Q4 FY2025 · quarter ended Mar 2026
Capital expenditures declines year over year
Q4 FY2025 capital expenditures of CA$1.11M (cash outflow) fell 64.8% year over year, behind the -41.0% change in trailing-twelve-month capital expenditures. Sequentially, it fell 57.3% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.
Context
- Capital expenditures amounted to 1.5% of revenue in FY2025, down 2.7 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -64.8% toward the trailing-twelve-month pace of -41.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CAD · from the cash flow
- Latest · FY2025
- (7.44M) CAD
- Year-over-year change
- +34.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | (7.44M) | +34.1% |
| FY2024 | 2025-03-31 | (11.28M) | -182.3% |
| FY2023 | 2024-03-31 | (4M) | +61.8% |
| FY2022 | 2023-03-31 | (10.45M) | +78.3% |
| FY2021 | 2022-03-31 | (48.11M) | — |
Capital Expenditures vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -41.0% is the 4th highest of 9, against a peer median of -69.7%.
- Capital expenditures amounts to 2.1% of revenue for CGC, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$22.56M CAD | +19.6% | +23.0% | 7.3% | |
| LTM Mar 2026 | $6.91M USD | — | -23.5% | 5.1% | |
| LTM Mar 2026 | CA$6.66M CAD | -41.0% | -10.7% | 2.1% | |
| LTM Mar 2026 | $2.22M USD | -88.8% | +26.2% | 0.9% | |
| LTM Mar 2026 | $1.16M USD | -4.6% | -65.6% | 2.8% | |
| LTM Mar 2026 | $623K USD | -8.4% | -68.2% | 2009.7% | |
| LTM Mar 2026 | $444K USD | -79.7% | -20.6% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K USD | -59.7% | +91.1% | 3.1% |
| LTM Mar 2026 | $81K USD | -99.8% | -43.2% | 1.0% | |
| LTM Mar 2026 | $3K USD | -97.1% | -37.0% | 0.0% | |
| Peer median (excluding CGC) | — | -69.7% | -23.5% | 2.9% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (258.91M) | (3.08B) | (483.68M) | (604.14M) | (366.64M) |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| Deferred Income Tax | (8.95M) | (5.73M) | 12.33M | 7.14M | 0 |
| Stock-Based Compensation | 46.69M | 25.32M | 14.18M | (4.21M) | 5.95M |
| Change in Working Capital | 205M | 58.97M | 3.97M | (31.97M) | 20.68M |
| Accounts Receivables | 16.15M | 6.24M | (3.75M) | (4.49M) | 25.69M |
| Inventory | 204.22M | 68.44M | 1.03M | (17.72M) | 3.71M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (15.37M) | (15.71M) | 6.68M | (9.77M) | (8.72M) |
| Other Non-Cash Items | (640.58M) | 2.36B | 118.08M | 424.3M | 200.17M |
| Operating Cash Flow | (545.81M) | (557.55M) | (281.95M) | (165.75M) | (88.98M) |
| Capital Expenditures | (48.11M) | (10.45M) | (4M) | (11.28M) | (7.44M) |
| Acquisitions (Net) | 103.2M | 14.93M | (955K) | (6.97M) | 0 |
| Purchases of Investments | (379.41M) | (67.15M) | (347K) | (95.34M) | 0 |
| Sales of Investments | 546.01M | 502.59M | 78.55M | 16.43M | 26.5M |
| Other Investing Activities | (2.3M) | (7.88M) | 167.79M | 48.9M | (48.83M) |
| Investing Cash Flow | 230.82M | 433.38M | 241.59M | (47.79M) | (29.77M) |
| Debt Repayment | (50.76M) | 16.98M | (509.78M) | (220.78M) | (24.62M) |
| Common Stock Issued | 2.7M | 1.05M | 81.06M | 385.39M | 374.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.53M | (37.72M) | (36.34M) | (15.96M) | 114.02M |
| Financing Cash Flow | (45.53M) | (19.69M) | (465.06M) | 148.66M | 463.57M |
| Effect of Forex Changes | (18.12M) | 44.86M | (1.29M) | 8.39M | 5.05M |
| Net Change in Cash | (378.65M) | (99M) | (506.71M) | (56.49M) | 349.86M |
| Free Cash Flow | (593.92M) | (568M) | (285.95M) | (177.03M) | (96.42M) |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.